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Mikrobiologie der Universitdt, Zurich, iMedizinische Poliklinik, Universitatspital,
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A total of 105 patients (mean age 57, range 15 to 90) with serious infections were
treated with intravenous ceftazidime, usually 2 g 8-hourly. Most patients had
complicating factors such as major surgery, cancer, chronic obstructive lung disease,
catheters or anatomical abnormalities. Eighty-seven infectious episodes in 77 patients
could be assessed for efficacy. Bacteraemia was diagnosed in 26% of these episodes.
Seventy-five per cent of infections were due to Gram-negative bacteria, Pseudomonas
aeruginosa being the most frequent. The major sites of infections were the lower
respiratory tract (30), the urinary tract (28), the soft tissues (9), the biliary tract (4),
bones (4) and the ears (4). Overall, 67% of the patients were cured, 20% improved,
7% relapsed and 6% failed to respond. Among the 27 infections due to Ps aeruginosa,
only two failures (in the same patient) and four relapses were recorded. However, in
the two failures and in three other cases with persistent Ps. aeruginosa colonisation,
the organism had become resistant to ceftazidime. Three failures were recorded in the
seven Staphylococcus aureus infections included in this study. Superinfection
occurred in four patients. Adverse events included rash (6), Clostridtum difficile
toxin-induced diarrhoea (3), transaminase elevation (3), weakly positive Coombs
test (10). Ceftazidime appears to be safe and effective for the treatment of severe
Gram-negative infections, including those caused by Ps. aeruginosa.
Introduction
Ceftazidime is a new cephalosponn which combines stability against a wide range of
/Mactamases and broad antibacterial spectrum in vitro (Neu & Labthavikul, 1982).
Its high intrinsic activity against a wide range of both Gram-positive and Gram-negative
organisms including Pseudomonas aeruginosa is of special interest for clinicians who have
to treat patients with severe infections before results of cultures and sensitivities are
known. In addition, and in contrast with most other cephalosporins, the low minimal
inhibitory concentrations of the drug against most Ps. aeruginosa strains suggest that
infections due to this organism can possibly be treated with ceftazidime alone.
These favourable properties prompted us to set up a multicentre study to investigate
the efficacy and toxicity of ceftazidime in a large number of patients with severe
infections.
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Patients and methods
The study was carried out in three teaching hospitals (Geneva, Lausanne and Zurich)
and two state hospitals (Fribourg and Liestal).
Patients with serious infections requiring treatment with a parenteral antibiotic were
eligible for this study. Patients known to be hypersensitive to cephalosporins or who had
a history of anaphylactic reaction to penicillin were excluded, as were pregnant women
and patients with neutropcnia.
The usual dosage regimen was 2 g eight-hourly of ceftazidime given intravenously by
a bolus injection or infusion over a 15- to 20-min period. When renal function was
significantly impaired the dosage frequency was reduced to 12-hourly in patients with
a glomerular filtration rate (GFR) of 30 to 15 ml/min and to 24-hourly dosing in patients
with a GFR of less than 15 ml/min. The protocol specified that the duration of treatment
should normally be between 7 and 10 days.
Samples for bacteriological culture and sensitivity testing were collected at the
following times: before treatment, 2 to 5 days and 8 to 10 days after the start of treatment,
48 to 72 h after stopping treatment and if possible 1 to 2 weeks after stopping treatment.
Pathogens were considered to be responsible for an infection if they were grown from
an appropriate specimen and if the clinical setting was consistent. For clinically
well-established lower respiratory tract infections with sputum yielding several different
organisms, it was not always possible to determine the pathogenic role of each. These
few cases were assessed on clinical grounds only. Disc sensitivity was performed either
by the Kirby-Bauer technique or the WHO-ICS method with discs containing 10 fig of
ceftazidime. The pathogens were considered to be sensitive if the zone diameter was
greater than 14 mm (Kirby-Bauer) or greater than or equal to 19 mm (WHO-ICS).
Minimal inhibitory concentrations were measured for most isolates by standard twofold
serial dilution method with an inoculum of 10* organisms per ml.
All patients had blood and urine specimens taken for haematological and biochemical
investigations at the following times: before treatment, 2 to 5 days and 8 to 10 days after
the start of treatment and 1 to 3 days after the end of treatment. In addition, if there
was any abnormality in the post-treatment sample, further samples were taken 1 to 2
weeks later.
Patients were considered as cured clinically when clinical abnormalities subsided with
no evidence of infection when the drug was discontinued or during follow-up. They were
considered as improved when clinical abnormalities subsided but with incomplete
resolution of infection. Relapse was denned as improvement on therapy with reappearance
during follow-up of an infection at the same site and isolation of the same organism.
Failure was defined as no apparent response to therapy. In addition to the initial
assessment made by each investigator all protocols were reviewed by one of us (P. F.).
Results
Sixty-two adult males and 43 adult females entered the study. One man was treated on
three separate occasions and one woman twice, giving a total of 108 cases treated. The
mean age for the males was 61-8 years (range 17 to 90) and for the females 520 years
(range 15 to 83). Twenty-two males and nine females were more than 70 years of age.
Eighty-two patients received 2 g 8-hourly of ceftazidime and nine patients 1 g 8-hourly.
Sixteen patients had pre-treatment renal impairment indicated by a decrease in creatinine
clearance and/or increase in serum creatinine and thus the frequency of dosing was
reduced.
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All patients were treated intravenously. In four patients this was changed to
intramuscular administration. The duration of treatment with ceftazidime ranged from
1 to 53 days. Most patients (58) were treated for 8 to 14 days. Four were treated for
less than 4 days, three because of early death and one because thetreatment was changed.
Seventeen patients were treated for four to seven days, 15 for 15 to 21 days and 14 for
more than 21 days. These 14 patients were treated for septic arthritis (2), complicated
otitis externa (2), lung abscess (2) and one each for osteomyelitis, otitis media, mediastin-
itis, infected tumour, meningitis, intraabdominal abscess, skin ulcer and septicaemia.
The MICs (micrograms per millilitre) of the main pathogens were as follows: E. coli,
< 003 to 8 0 (mean: 007), Ps. aeruginosa, 005 to 4 0 (mean: 0-63), Klebsiella sp., 006
to 16 (mean: 011), Enterobacter sp., < 003 to 0-25 (mean: 008), Staph. aureus, 4 to
16 (mean: 4-5).
Although all patients were included in the assessment of toxicity of ceftazidime, 28
cases had to be eliminated for the final assessment of efficacy, 4 because duration of
treatment was too short, 9 because other antibiotics were administered, 4 because
multisystem failure precluded any judgment on the efficacy of the drug, 7 because
infection was ultimately not confirmed, and 4 because cultures obtained before initiation
of therapy yielded ceftazidime-resistant organisms (3 Streptococcus faecalis, 1 Aspergillus
fumigatus). Thus, from a total of 105 patients with 125 infections, 77 patients with 87
infections were assessable for efficacy (Table I). In over 80% of the cases the infection
was judged as being severe by the clinician. The majority of patients were treated for
lower respiratory tract infections (30) and urinary tract infections (28). In 22 of these
86 infections bacteraemia was demonstrated. Overall, 67% of the patients were cured,
20% improved, 7% relapsed and 6% failed to respond to ceftazidime.
Pneumonias
Twenty-four pneumonias were clinically assessable. Eleven were hospital-acquired,
mostly after extensive neck (3) or thoracic (1) surgery for cancer, heart surgery (3) or
major abdominal pathology (2). Two patients were intubated, one for a Guillain-Barre
syndrome, the other after acute coronary bypass. Among the 13 community-acquired
pneumonias, 4 were secondary to aspiration and 9 afflicted patients with various
underlying debilitating diseases, such as chronic obstructive lung disease (6), cirrhosis
(3), cardiac insufficiency (3), autoimmune (3) and neurological (3) disorders, cancer (3),
and diabetes (1). Furthermore, 5 patients with pneumonia had already been treated
unsuccessfully with antibiotics and 3 had cavitating lesions (Ps. aeruginosa 2, Enterobacter
aerogenes 1). In three patients, bacteraemia was diagnosed before therapy started.
Fourteen pneumonias were due to Gram-negative bacteria, Ps. aeruginosa represent-
ing nine of them. Thirteen were cured or improved. Of the two patients who improved,
one subsequently developed positive blood cultures for Bacteroides fragUis and Candida
albicans due to a concomitant ischaemic colitis. One failure possibly due to the develop-
ment of ceftazidime-resistant Ps. aeruginosa was recorded in a patient with extensive
neck surgery for metastatic cancer. Four out of the nine patients infected with Ps.
aeruginosa remained colonized with the organism although infection was cleared
clinically and radiologically. In three of the four patients with persisting Pseudomonas
and in the above-mentioned failure the organisms had become resistant to ceftazidime.
In the two instances in which the initial sensitive and subsequent resistant isolates were
pyocin-typed, they were identical (Blaser et al., 1983). However, clinically, in only a
single case did this resistance contribute to a definite clinical failure.
Failures were recorded in the two Staph aureus pneumonias, despite sensitivity to
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Site of
infection (no.)
Pneumonia (24)
Bronchitis (6)
Urinary tract
infections (28)
Biliary tract
infections (4)
Enterocolitis (1)
Peritonitis (2)
External otitis (4)
Osteoarthritis (2)
Diabetic foot (2)
Surgical wounds (4)
Cellulitis (4)
P.
Pathogens
Ps aeruginosa
E. coli
E. coli
A. calcoaceticus
K. oxytoca
Enterobacter sp.
Staph. aureus
Strep, pneumoniae
Unidentified
Unidentified
E. coli
K. pneumoniae
Ps. aeruginosa
E. coli
K. pneumoniae
Ps. aeruginosa
Salm. typhimwixon
Staph. aureus
K. pneumoniae
Ps. aeruginosa
Ps. aeruginosa
Ps. aeruginosa
Group B strep-
tococcus
Ps. aeruginosa
Staph. aureus
Frandoli <
Table I
No. of
cases
•taL
(no. with
bac-
teraemia) Outcome
9(1)
KD
10)
1
2
2
3
5
6
18(9)
5(1)
5d)
2(2)
KD
1
1
1
1
4
2
1
1(1)
4
3
Staph. aureus, E. coli 1
Salm. typhimwium
5 cured
3 improved
1 failed
1 cured
1 cured
1 cured
2cured
1 failed
1 failed
3 cured
5 cured
6 improved
18cured
5 cured
3 cured
2 relapsed
1 cured
1 improved
1 improved
1 improved
1 improved
1 failed
1 failed
2cured
2 relapsed
2 cured
1 improved
1 improved
• 1 cured
2 improved
1 failed
2 cured
1 improved
1 cured
Remarks
One case with superinfec-
tion with Bact.fragilis
and C. albicans
Emergence of ceftazidime-
resistant P. aeruginosa
Pleurotracheal fistula
Positive blood culture on
ceftazidime
One case with bladder
diverticula
Ultimately cured by surgery
Ultimately cured by surgery
Ultimately cured by surgery
Carrier at the end of
ceftazidime
Development of S. aureus
peritoneal abcess while
on ceftazidime
Development of ceftazidime-
resistant Citrobacter and
lateT Str.faecalis intra-
abdominal abscess
Ps. aeruginosa remained
sensitive
+ Debridement and
gentamicin beads
+ Surgical debridement
+ Surgical debridement
(ultimately cured)
Development of ceftazidime-
resistant Ps. aeruginosa
+ Debridement and graft
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Site of
infection (no.)
Mediastinitis (1)
Gonococcacmia (1)
Epididymitis (1)
Meningitis (1)
Intravenous
catheter (2)
Pathogens
Provid. Stuart ii
N. gonorrhoeae
E. coli
Ps. aeruginosa
K. pneumoniae
Ent. cloacae
No. of
cases
(no. witl
bac-
l
teracmia) Outcome
1(1)
1(1)
1
1
1(1)
KD
1 cured
1 cured
1 cured
1 cured
1 relapsed
1 cured
Remarks
Cotrimoxazole treatment
during follow-up
Developed while patient
was on ticardllin
and tobramycin
Re-infection of new
catheter while on ceftazidine
ceftazidime. One patient had a pleurotrachcal fistula, secondary to extensive thoracic
surgery for lung cancer. The other developed bacteraemia after 5 days of treatment and
was subsequently cured by other antibiotics.
Eight patients with community-acquired pneumonia had sputum growing mixed
bacterial flora, including Str. pneumoniae in three instances. All were cured.
Three patients with pneumonia died, but in one instance only did infection contribute
to the death. Two additional deaths from pneumonia, both due to Strep, pneumoniae,
have not been included because they occurred during the first 24 h. Two additional
failures were observed in patients infected with pathogens which turned out to be
resistant to ceftazidime (Str. faecalis, Aspergillus fumigatus) and were therefore not
included.
Bronchitis
Six cases of severe bronchitis with abundant purulent sputum in patients with severe
predisposing pulmonary diseases improved markedly on ceftazidime. Organisms isolated
from sputum included a variety of Gram-negative organisms (E. coli, Enterobacter sp.,
K. pneumoniae, H. influenzae) in mixed cultures, but their pathogenic role in each
individual case was difficult to assess.
Urinary tract infections
Urinary tract infections, defined as > 10* bacteria/ml of urine, accounted for 28 cases.
Twenty were considered as upper tract infections because of fever, loin pain and positive
blood cultures in 12 instances. Sixteen cases had underlying factors either predisposing
to infection or complicating treatment (Foley catheters 7, urinary tract abnormalities 7,
renal transplant 2). The pathogens were the usual bacteria involved in urinary tact
infections, Ps. aeruginosa being somewhat over-represented because of the drug studied.
Twenty-four were clinically and bacteriologically cured with a negative urine culture
obtained at least 1 week after treatment stopped. Two cases were clinically cured but
bacteriologically unassessable because they received other antibiotics during the follow-up
period. Two relapses occurred, both in patients with Ps. aeruginosa infections. Only one
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of the two patients had an underlying urinary tract abnormality. In both cases the initial
and final isolates were sensitive to ceftazidime.
Biliary tract and abdominal infections
Four patients had biliary tract infection, three of them with positive blood cultures. In
the fourth, the bile obtained by a percutaneous drain was positive for Ps. aeruginosa. One
patient was cured with antibiotic alone, while the other three improved markedly on
therapy and were eventually cured when surgery was performed. The patient infected
with K. pneumoniae still harboured sensitive AL pneumoniae in the bile obtained during
an operation performed after 2 weeks of therapy. Two patients were treated with
ceftazidime because of fever occurring after abdominal surgery for perforated ulcer and
pancreatitis with intra-operative cultures positive for Staph aureus and K. pneumoniae,
respectively. On therapy, they developed clinically detectable abdominal abscesses due
to Staph. aureus in one case and to ceftazidime-rcsistant Citrobacter sp. in the other case.
One patient with Salmonella typhimurium enterocolitis was cured clinically but still
harboured Salm. typhimurium at the end of a 14 day course of ceftazidime.
External otitis
Four patients had severe purulent Ps. aeruginosa otitis with chondritis and abscesses.
Two had had tympanoplasty. Three had been treated unsuccessfully by surgery and other
antibiotics. All responded to ceftazidime, but two relapsed after 15 and 90 days despite
3 and 6 weeks of ceftazidime therapy, respectively. In both cases, the Ps. aeruginosa were
still sensitive to ceftazidime.
Skin and wound infections
Four patients had surgical wound infections. Three improved on ceftazidime in
association with surgical debridement and were eventually cured, one at the time when
the drug was stopped, the other two a few weeks later without further therapy. One
patient with cheek cancer and concomitant bacteraemic Ps. aeruginosa pneumonia failed
to respond, developed resistant Ps. aeruginosa wound infection and eventually died from
multisystem failure. Four patients had severe cellulitis complicating underlying skin
diseases. Two were cured and one improved with ceftazidime alone.The fourth required
surgical debridement and skin graft.
Osteoarthritis
Two patients with Ps. aeruginosa chronic osteoarthritis were cured (with a follow-up of
3 and 6 months) with surgical debridement, local gentamicin beads (removed after 10
and 30 days, respectively) and 6 weeks of ceftazidime therapy. Two patients with diabetic
foot infections were admitted in hospital for amputation. On ceftazidime they improved
markedly and amputation could be postponed.
Miscellaneous infections
Two intravenous catheter septicaemias and one case each of mediastinitis, epididymitis,
gonococcaemia and meningitis were also treated with ceftazidime. All except one were
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cured. One patient with intravenous catheter-related K. pneumoniae septicaemia had a
clinical relapse with K. pneumoniae infection of a newly placed catheter. The organism was
still sensitive to ceftazidime.
Of note is the cure of a post-traumatic ticarcillin-resistant Ps. aeruginosa meningitis
which developed while the patient was on ticarcillin and tobramycin. Forty-eight hours
after initiation of therapy the CSF ceftazidime level was 40 mg/1, while it fell to < 1 mg/1
after 3 weeks of therapy when signs of meningeal inflammation had disappeared.
Adverse events
Superinfection occurred in 4 patients (C. albicans and Bact.fragilis septicaemia, Candida
krusei urine infection, Str.faecalis bacteraemia, Citrobacter sp. intra-abdominal abscess)
and colonization with Str. faecalis in two patients (urine, wound).
In addition, 10 patients experienced adverse events which were attributed to
ceftazidime. In one patient, there were four repeated occurrences until a central venous
two cases. Skin rashes were observed in six cases (associated with pruritus in one case).
In one patient, treatment was continued and the rash disappeared. With the other two
patients, the rash did not disappear until treatment was stopped, but the drug was
discontinued because it was no longer needed therapeutically and not because of the rash.
One patient developed a fever which was well tolerated despite further ceftazidime
treatment.
There were six cases of intravenous catheter thrombophlebitis possibly related to
ceftazidime. In one patient, there were four repeated occurrences until a central venous
catheter was placed. Five cases of diarrhoea were observed. Cl. difficile and its toxin were
identified in the stools of the three patients in whom it was looked for. Vancomycin was
given for the first two, although symptoms had already started to resolve in one of them.
The diarrhoea resolved spontaneously after ceftazidime was stopped in the last case.
Increase in serum creatinine which could possibly be related to ceftazidime was noted
in one patient, but this patient already had renal impairment secondary to hypertension,
and deterioration could be attributed to several conditions other than ceftazidime.
Slight changes in the results of liver function tests were noted in three patients. In one,
SGPT returned to normal 10 days after ceftazidime was stopped. In the other two
patients with increase in both SGOT and SGPT, further follow-up was not available.
No prothrombin time alteration was observed. A weakly positive direct Coombs test
occurred in ten patients, none of whom had evidence of haemolysis.
Discussion
The present study demonstrates the clinical efficacy of ceftazidime in various severe
infections occurring in debilitated patients and due to a wide range of bacteria. Overall,
87% of patients were cured or improved.
Of special interest are the good results obtained in Ps. aeruginosa infections with
ceftazidime as single agent. Among the 27 infections due to this pathogen in the present
series, there were only 2 failures and 4 relapses. The two failures were recorded in the
same patient, who had simultaneously pneumonia and a wound infection, with the
appearance of ceftazidime-resistant Ps. aeruginosa at both sites during treatment. Four
relapses occurred, two in patients with severe otitis, a disease known to be very difficult
to cure, and two in patients with urinary tract infections, one of whom had underlying
urinary tract abnormality. In all four cases, the Ps. aeruginosa isolates were still sensitive
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to ceftazidime at the time of relapse. The other 21 Ps. aeruginosa infections were
successfully treated with ceftazidime (in association with surgery when indicated), and
included problem infections such as excavating pneumonia, osteoarthritis, severe soft
tissue infections, external otitis and meningitis. The rapid development during treatment
of ceftazidime-resistant Ps. aeruginosa at the site of infection, as observed in the sputum
of 4 out of 9 patients with Ps. aeruginosa pneumonia, is a cause of concern. Similar
observations have been reported by others for Ps. aeruginosa as well as for Enterobacter
(Eron et al., 1983). The pyocin-typing of Ps. aeruginosa performed in two of our cases
suggests that the development of resistance was due to the induction of resistance in the
original sensitive strain rather than to the selection of a natural resistant strain or to the
acquisition of a resistant strain from the environment. However, in one patient only did
this phenomenon contribute to a clinical failure, and its clinical importance remains to
be defined.
The minimal inhibitory concentrations of ceftazidime for Staph. aureus are notably
higher than those of other cephalosporins (van KJingerer (1981)). In the present study,
we treated seven Staph. aureus infections. Three of the four cases of cellulitis complicating
various skin disorders were cured or improved by ceftazidime alone, and one with
ceftazidime combined with surgical debridement. In contrast, ceftazidime failed in the
two Staph. aureus pneumonias, in one case possibly because of the presence of an
anatomical defect, but in the other case without detectable factors contributing to the
persistence of infection. The latter case developed Staph. aureus bacteraemia while
receiving ceftazidime and was switched to flucloxacillin and ultimately cured. Another
failure was recorded in a patient who presented with Staph. aureus peritonitis following
a perforated duodenal ulcer. On ceftazidime therapy he developed an intra-abdominal
abscess due to Staph. aureus.
Ceftazidime was well tolerated in all except five patients (3 with rashes and 2 with
diarrhoea), who required discontinuation of the drug. There were three cases of Cl.
difficile toxin-induced diarrhoea. In contrast with some other new cephalosporins, no
prothrombin time alteration was observed. Superinfection occurred in four cases and
colonization with resistant organisms in two cases (excluding the above-mentioned Ps.
aeruginosa cases).
In conclusion, ceftazidime proved to be safe and effective for the treatment of various
severe infections due to Gram-negative bacteria including Ps. aeruginosa, but failures
observed in three out of seven Staph. aureus infections in the present study gives rise
to concern. The clinical importance of emergence of resistance during therapy should
be further explored.
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